title: Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
abstract: Farnesoid X receptor and Takeda G-protein-coupled receptor-5 are well known bile acid receptors and act as promising targets for the drug development and treatment of diabetes. Agonists of both the bile acid receptors increase insulin sensitivity and control glucose, lipids and bile acid homeostasis. The current study deals with the identification of novel dual agonists using ligand and structure-based virtual screening. Initially, an experimentally proven well-known dual agonist of FXR and TGR5, namely INT-767, was docked into the binding sites of FXR and TGR5 to determine the protein residues important for ligand binding. The docked complexes FXRINT-767 and TGR5INT-767 were used to generate e-pharmacophore hypotheses. Ligand-based virtual screening was carried out using the hypothetical e-pharmacophore model against the ChemBridge database. Further, structure-based virtual screening was performed with screened hits to find potential agonists of FXR and TGR5. A total of four best agonists were identified based on their affinity and mode of interactions with the receptors. The binding mode of these compounds with both receptors was analyzed in detail. Furthermore, molecular dynamics, ADME toxicity prediction, density functional theory and binding free energy calculations were carried out to rank the compounds. Based on the above analyses, the most potent compound, ChemBridge_9149693, was selected for further in vitro studies. The results of in vitro assays suggested that ChemBridge_9149693 is a potent and promising drug for the treatment of type II diabetes. Thus, the compound could be used for further drug design and development of dual agonists of FXR and TGR5.
authors: Molecular Biology Lab, Department of Bioinformatics, Alagappa University, Karaikudi, Tamilnadu-630004, India. sri.bioinformatics@gmail.com.
authors: Thangaraj
authors: T
authors: Sindhu
authors: Pappu
authors: P
authors: Srinivasan
mesh_terms: D001665:Binding Sites; D002460:Cell Line; D002470:Cell Survival; D003198:Computer Simulation; D055808:Drug Discovery; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000819:agonists* / Q000737:chemistry*; D006801:Humans; D006860:Hydrogen Bonding; D008024:Ligands; D008958:Models, Molecular; D008968:Molecular Conformation; D062105:Molecular Docking Simulation; D056004:Molecular Dynamics Simulation; D011485:Protein Binding; D043562:Receptors, G-Protein-Coupled / Q000819:agonists* / Q000737:chemistry*; D015203:Reproducibility of Results; D013329:Structure-Activity Relationship
chemical_list: D051860:Fragile X Messenger Ribonucleoprotein 1; D008024:Ligands; D043562:Receptors, G-Protein-Coupled; C473772:GPBAR1 protein, human